This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2022 Feb:142:258-260.

doi: 10.1016/j.jclinepi.2021.10.026. Epub 2021 Nov 5.

Missing trials in drug regulatory dossiers may have good reasons, but should be predefined and transparent

Hubert G Leufkens¹

Affiliations

Affiliation

¹ Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, PO Box 80 082, 3508 TB Utrecht, The Netherlands. Electronic address: h.g.m.leufkens@uu.nl.

PMID: 34748906
DOI: 10.1016/j.jclinepi.2021.10.026

Free article

Missing trials in drug regulatory dossiers may have good reasons, but should be predefined and transparent

Hubert G Leufkens. J Clin Epidemiol. 2022 Feb.

Free article

. 2022 Feb:142:258-260.

doi: 10.1016/j.jclinepi.2021.10.026. Epub 2021 Nov 5.

Author

Hubert G Leufkens¹

Affiliation

¹ Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, PO Box 80 082, 3508 TB Utrecht, The Netherlands. Electronic address: h.g.m.leufkens@uu.nl.

PMID: 34748906
DOI: 10.1016/j.jclinepi.2021.10.026

No abstract available

PubMed Disclaimer

Comment in

Missing trials from regulatory document of methylphenidate for adults with attention-deficit/hyperactivity disorder: Response to Boesen et al.
Jaeschke RR. Jaeschke RR. J Clin Epidemiol. 2022 May;145:185-186. doi: 10.1016/j.jclinepi.2021.12.020. Epub 2021 Dec 16. J Clin Epidemiol. 2022. PMID: 34923025 No abstract available.

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science